中國創新投資(01217.HK)中期盈轉虧至1875.5萬港元
格隆匯 8 月 20日丨中國創新投資(01217.HK)公告,截至2020年6月30日止6個月,公司錄得出售證券所得款總額約為2.88億港元(截至2019年6月30日止6個月:1.35億港元)。期內及公司擁有人應占虧損1875.5萬港元,去年則盈利2385.5萬港元,盈轉虧;每股基本虧損0.146港仙;不派息。
憑藉多年來在中國內地經驗及廣闊人脈,公司近期分別透過投資儲能產品、光源產品、節能材料、健康通訊及資產管理,以節能減排為發展目標,實現了在"新能源"、"新光源"、"新材料"、"新健康"及"新資"五個產業領域實質項目突破。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.